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The symptoms of chronic heart failure (CHF) are predomi- 
nantly shortness of breath and fatigue during exercise and 
reduced exercise capacity. Disturbances of central hemodynamic 
function are no longer considered to be the major determinants of 
exercise capacity. The two symptoms of fatigue and breathlessness 
are often considered in isolation. A pulmonary abnormality is 
usually considered to be the cause of abnormal ventilation, and 
increased dead space ventilation has come to be accepted as a 
major cause of the increased ventilation relative to carbon dioxide 
production seen in CHF. Rather than decreased skeletal muscle 
perfusion, an intrinsic muscle abnormality is considered to be 
responsible for fatigue. Another abnormality seen in CHF is 
persistent sympathetic nervous system activation, which is difli. 
cult to explain on the basis of baroreflex activation. There is 
increasing evidence for the importance of skeletal muscle ergore- 
ceptors or metaboreceptors in CHF. These receptors are sensitive 
to work performed, and activation results in increased ventilation 
and sympathetic activation. The ergoreflex appears to be greatly 
enhanced in CHF. We put forward the "muscle hypothesis" as an 
explanation for many of the pathophysiologic events in CHF. 
Impaired skeletal muscle function results in ergoreflex activation. 
In turn, this causes increased ventilation, thus linking the symp- 
toms of breathlessness and fatigue. Furthermore, ergoreflex stim- 
ulation may be responsible for persistent sympathetic activation. 
(J Am CoU Cardiol 1996;28:1092-102) 
Patients with chronic heart failure (CHF) stop exercising at 
lower work rates than do normal subjects. At first, the mech- 
anism seems imple; patients with heart failure have impaired 
cardiac function, which results in an inability to raise cardiac 
output in response to exercise. "Backward failure" leads to 
breathlessness, and "forward failure" to fatigue. The failing left 
ventricle, fully utilizing the Frank-Starling mechanism, is sup- 
ported by increased filling pressures, which in turn may result 
in pulmonary congestion or even edema. This can cause 
derangement to gas transfer and lung mechanics, leading to 
breathlessness. The failure of the heart to generate a sutficient 
output could cause fatigue secondary to poor skeletal muscle 
perfusion. However, evidence suggests that hemodynamic 
function is poorly related to exercise capacity and symptom 
generation i CHF, and points increasingly toward the periph- 
ery as an important determinant of both shortness of breath 
and fatigue. 
In this report, we review the pathophysiology of exercise 
limitation in CHF and discuss possible future lines of inquiry. 
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Most studies addressing this subject have used incremental 
exercise tests with metabolic gas exchange measurement to
derive peak oxygen consumption (peak Vo2), an index of 
exercise capacity. In CHF, peak Vo2 is reduced. Whether this 
is the most appropriate way to assess exercise function has 
been disputed, as different exercise protocols elicit different 
measurements of peak 902 (1-3) and may not reflect everyday 
activity (4); nevertheless, peak 9o2 is relatively reproducible 
and free of observer bias (5-7), and the method also allows 
ventilation (9E) and carbon dioxide consumption (9coz) to be 
measured. The understanding of exercise limitation has in- 
creasingly involved an exploration of the possible causes of 
reduction of peak 9o2. 
Symptoms 
The major symptoms of CHF are breathlessness and fatigue 
during exercise. Exploration of the mechanism of exercise 
limitation has tended to concentrate on the genesis of one or 
the other symptom with the tacit assumption that there are two 
groups of patients--one limited by some abnormality of 
skeletal muscle who complains of fatigue, and one in whom 
abnormalities of ventilation predominate and who complains 
of breathlessness. However, the same patients complain of 
different symptoms during different ypes of exercise (8). Cycle 
exercise predominantly leads to fatigue and treadmill exercise 
to breathlessness (9). Even using the same exercise mode, the 
symptom at peak exercise depends on the speed of the pro- 
tocol (8), even when peak pulmonary artery pressures are the 
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Abbreviations and Acronyms 
ACE : angiotensin-convcrting e zyme 
ATP = adenosine triphosphate 
CHF : congestive heart failure 
PCr : phosphocreatine 
Pa = inorganic phosphate 
"qc% :- carbon dioxide consumption 
'¢E expired volume 
Vo~ oxygen consumption 
same (10). Data from the Studies of Left Ventricular Dysfunc- 
tion (SOLVD) show that breathlessness a a symptom is of 
little relevance in predicting outcome compared with measures 
of exercise capacity (11). We have shown in 202 patients that 
there is little difference in clinical characteristics between those 
stopped by breathlessness and those stopped by fatigue in 
terms of peak 9o 2, ventilatory response to exercise or the 
etiology of heart failure (12). Rather than there being two 
groups of patients, breathlessness and fatigue may represent 
the same process or signal and may be generated by a similar 
underlying pathophysiologic mechanism. 
Central Hemodynamic Function 
It has been appreciated for some time that there is a weak 
relation between indexes of central hemodynamic function and 
exercise capacity (13). Although untreated patients with CHF 
have raised total body water and sodium (14), fluid compart- 
ments return to normal when the patients are optimally treated 
(15). The lack of a relation between left ventricular filling 
pressure and peak 902 (9,16) is thus not surprising. Similarly, 
there appears to be almost no relation between left ventricular 
function as measured by ejection fraction, rest cardiac output 
and exercise capacity (9,16-18). 
If central hemodynamic variables are improved quickly with 
vasodilators (9,19,20) or with inotropic support (21), or even 
cardiac transplantation (22,23), there is no immediate change 
in exercise performance but rather a gradual improvement 
over weeks and sometimes months. In normal subjects, exer- 
cise capacity seems ultimately to be limited by cardiac output; 
increasing the exercising muscle bulk by adding arm to maximal 
leg exercise does not result in an increase in Vo2, suggesting 
that cardiac output and oxygen delivery is already maximal. In 
patients with CHF, the addition of arm to maximal leg exercise 
does produce a further increase in 902 (24). These findings 
imply that the ability of the muscle to extract oxygen, for 
whatever reason, rather than the heart o deliver oxygen, is the 
major determinant of exercise capacity. Altered cardiac func- 
tion could, however, lead to secondary changes in the periph- 
ery, which in turn may determine xercise performance; these 
secondary changes may take months to return toward normal 
after hemodynamic improvement. 
Pulmonary hemodynamic variables may be more important 
in determining exercise capacity (25). Some investigators have 
found weak correlations between peak 902 and pulmonary 
vascular resistance (26) and pressure (26) and pulmonary 
capillary wedge pressure (27). Baker et al. (28) found a close 
relation between peak 902 and right ventricular ejection 
fraction. We studied this relation in a group of patients with 
CHF and in patients who had undergone the Fontan proce- 
dure for congenital heart disease (29). Patients with a previous 
Fontan operations had no functional right ventricle, as the 
systemic venous return was routed into the pulmonary arterial 
tree directly (30,31). Exercise capacity was normal in many 
patients. Those with reduced exercise capacity had an in- 
creased ventilatory response to exercise. Thus, despite the 
absence of right ventricular function, exercise capacity may be 
unrestricted and the ventilatory response to exercise normal. 
The relation between ventilatory response and exercise capac- 
ity seen in the patients with CHF (32,33) was also seen in 
patients with no right ventricle. 
Pulmonary Function 
A close correlate of peak 902 in CHF is the ventilatory 
response to exercise. There is an increase in ventilation at a 
given level of exercise (9,34-37), and this is well characterized 
as an increase in the slope of the relation between ventilation 
and carbon dioxide production (VENC% slope). That is, at any 
given level of carbon dioxide production, minute ventilation is 
increased (32,33). An explanation for the exercise limitation in 
CHF must include an explanation for the increased ventilatory 
response. 
This raises the crucial question of what drives ventilation 
during exercise. The linearity of the relation between Vco 2 and 
9E persuades many investigators that the primary ventilatory 
stimulant is carbon dioxide production. If so, then it might be 
anticipated that there should be a change in arterial partial 
pressures of blood gases as the initiating event in a feedback 
loop; however, arterial blood gases during exercise suggest, if 
anything, that hyperventilation is taking place with respect o 
blood gases (34,38). In those patients suspected of having 
CHF, abnormalities of blood gases are uncommon, and are 
associated with some other pathologic finding (39). The impli- 
cation is that Vco 2 does not drive ventilation; rather, carbon 
dioxide is excreted by the lungs as a function of the mixed 
venous carbon dioxide tension and the minute ventilation. Any- 
thing that increases ventilation will thereby increase Vco 2. This is 
an important distinction; if Vco 2 follows ventilation, then there is 
a nonpulmonary ventilatory stimulus. It is possible that subtle 
changes or oscillation around the same mean level of blood gas 
tensions carries the ventilatory signal. There is some evidence for 
an increased chemosensitivity for hypoxia in CHF (40). 
If Vco 2 is assumed to be the principal ventilatory stimulus, 
then analysis of the alveolar ventilation equation* leads to the 
*VE - 9"C02 × 863/Paco z x (1 VD/VT), where VD/~ x describes dead 
space ventilation as a proportion of tidal ventilation: Paco 2 is the arterial partial 
pressure of carbon dioxide; and 863 is a constant to standardize gas measure- 
ments to body temperature, pressure and saturation. 
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conclusion that the increased VENco2 slope must be caused by 
an increase in dead space ventilation (36,37). This has received 
some support (41,42) and forms an attractive theory; the failing 
right ventricle would result in decreased perfusion of the lung 
apices, with an increase in dead space ventilation. The respi- 
ratory pattern might change with an increase in rate at the 
same minute ventilation, causing greater ventilation of the 
fixed anatomic dead space (43). Davies et al. (44) reported a
reduction i  pulmonary capillary permeability, which related to 
the duration of heart failure, and Puri et al. (45) related this 
abnormality to increased resistance at the alveolar/capillary 
membrane. This potentially increases the proportion of venti- 
lated alveoli that do not contribute to gas exchange. 
Such an analysis of metabolic gas exchange has potential 
flaws. The alveolar ventilation equation only applies in steady 
state conditions, which do not exist in the rapidly incremental 
exercise protocols used in many studies (41,42). Indeed, during 
exercise with rapidly incremental stages, the VENco2 slope is 
seen to increase further (46). Second, using the alveolar 
ventilation equation forces dead space to be the cause of the 
increased '¢ENco2 slope rather than the result of an increase 
in ventilation; no other factor can be invoked. Some anomalies 
arise in the interpretation f some studies. Wada et al. (42) 
found a greater "QE/Vco 2 slope in a subgroup of patients with 
a fall in dead space ventilation than that observed in control 
subjects, while at the same time concluding that dead space 
was a critical abnormality. 
Rajfer et al. (47) used different methods to determine dead 
space fraction and found a fall in dead space in patients with 
heart failure during exercise. They also found hyperventilation 
relative to arterial blood gas tensions. We found no relation 
between right ventricular function and ventilation (29). In 
other experiments, we found that altering the respiratory rate 
at the same minute volume causes no change in the VENco 2 
slope, at least in normal subjects (48), so that an alteration i  
respiratory pattern cannot explain the change in CHF. 
The other possible component toventilation-perfusion mis- 
match is an increase in perfused but underventilated areas of 
lung. If present, this shunt would result in an increase in the 
alveolar arterial oxygen difference and arterial desaturation. 
Small increases in alveolar arterial oxygen difference have been 
reported (38,47). Other workers have suggested that exercise 
capacity is increased in patients with heart failure by supple- 
mental oxygen (49). However, in the absence of any significant 
abnormality ofarterial oxygenation i the majority of patients 
with CHF (39), ventilation-perfusion matching isunlikely to be 
as important as is often concluded. 
Evidence for Role of the Periphery 
If ventilation-perfusion mismatch isnot the major cause of 
increased ventilation, then there must be a non-carbon dioxide 
signal to ventilation to explain the hyperventilation with re- 
spect to '¢co 2. This certainly fits the observed behavior of 
arterial blood gases where Pac% is observed to fall during 
exercise. Further support comes from a closer analysis of the 
",?ENCO 2 relation. The work of Metra et al. (41) showed that 
the '~ENco 2slope calculated from the data acquired early in 
exercise is a remarkably poor predictor of the slope calculated 
from the exercise data as a whole (50). We have shown that in 
patients with CHF, the instantaneous VENco2 ("ventilatory 
equivalent for carbon dioxide") rises toward the end of exer- 
cise, and that the more severe the heart failure, the more the 
~QE/Vco 2 deviates from a straight line relation (51). These 
observations suggest that there is a non-carbon dioxide stimu- 
lus to ventilation of increasing importance as the severity of 
CHF increases, causing progressively greater ventilatory re- 
sponse to exercise. 
What is the origin of such an abnormal ventilatory stimulus 
and could it also explain the sensation of breathlessness? 
Increasingly, the evidence points toward abnormalities of 
skeletal muscle as being the source of both the symptoms of 
exercise intolerance and the excessive ventilatory response in 
patients with CHF. 
Skeletal Muscle in CHF 
Structure. The histologic appearance ofskeletal muscle in 
chronic heart failure has been reported to be abnormal in 
many studies (Table 1). An early study examining forelimb 
biopsies found increased lipid deposits and endomysial fibrosis 
(52). Lipkin et al. (53) reported on patients with severe CHF 
and described an increase in muscle fiber size variance, with a 
shift toward type II fibers. There were atrophic fibers and 
intracellular lipid droplets. Mancini et al. (54) reported ashift 
toward type lib fibers in CHF and atrophy of type IIa fibers, 
and the presence of type IIc fibers in a study of 22 patients and 
8 control subjects (54). In this study, type I fibers were not 
found to be significantly reduced. Capillary density per fiber 
was unchanged in patients with CHF compared with control 
subjects but was increased when expressed per square milli- 
meter. 
Sullivan et al. (55) found a reduction in type I fibers and a 
shift toward type IIb fibers. Type IIc fibers were seen in one 
control subject only. The type IIb fibers were smaller in 
patients with CHF than in control subjects. The ratio of 
capillaries to fiber cross-sectional rea was unchanged; as the 
fibers were smaller than normal, the number of capillaries per 
fiber was reduced. Drexler et al. (56) examined biopsies in 57 
patients and 18 control subjects to assess mitochondrial struc- 
ture. Type I fibers were reduced and type II fibers relatively 
increased (subtypes of type II fibers were not measured). The 
volume density of mitochondria and surface density of cristae 
were reduced, a finding more marked in the more severely 
exercise-limited subjects. In a subset of patients, capillary 
length density (a measure of the length of blood capillaries per 
unit volume of muscle tissue) was reduced. 
Biochemistry. Associated with the histologic abnormali- 
ties, there is a reduction in the oxidative nzymatic capacity of 
the muscles. There is a reduction in beta-hydroxyacyl oen- 
zyme A dehydrogenase activity (an enzyme mediating fatty 
acid oxidation), but levels of citrate synthase, lactate dehydro- 
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Table I. Summa~' of Skeletal Muscle Changes in Chronic Heart Failure 
Investigators (ref no.) 
Lipkin et al. (53) Mancini et al. (54) Sullivan eI al. (55) Dre:der et al. (56) Ralston et al. (58) Broqvist et aL (59) 
Fiber type 
i $ 
Ila 
lib ( 7 ) 
Ilc 
Glycolytic pathway 
Krehs' cycle 
Lipid oxidation 
Ox phos 
ATP/CrP 
Mitochondria 
t 
$ 1 
Capilla~, density per ~ ,~ 
fiber or per mm 2 T 
Other findings Intracellular ipid, Type II fiber size ~, Type II fiber size ,, 
fiber atrophy 
(t) 
$ 
$ Volume 
,1, Cristae 
1 
There is a generalized shift away from type I (slow twitch, aerobic) toward type II (fast twitch, anaerobic) fibers. Although the glycolytic pathway appears to be unaffected, 
there is a reduction in oxidative capacity, including that for beta-oxidation f fatty acids. There is a generalized reduction in capillary density, although whether there is a 
reduction per muscle fiber remains unclear. ATP = adenosine triphosphate; CrP = creatine phosphate; Lipid oxidation = hydroxyacyl coenzyme A dehydrogenase activity; 
Ox phos = oxidative phosphorylation e zymes; ref - reference; ,~ = decreased; ,~ = unchanged; I' = increased; ( 1" ) fiber subtypes not reported. 
genase and phosphofructokinase r  normal (54). Sullivan et 
al. (55) reported normal evels of glycolytic enzymes with a 
reduction i  enzymes of the Kreb's cycle. Biopsies taken during 
exercise (57) showed that glycolysis and glycogenolysis were 
accelerated in patients with CHF compared with control 
subjects, but lactate accumulation a d phosphocreatine (PCr) 
depletion were decreased at peak exercise. Drexler et al. (56) 
found a reduction in cytochrome oxidase, which correlated 
with the severity of heart failure, and other workers have found 
reduced citrate synthase, succinate dehydrogenase and cyto- 
chrome oxidase (58). Broqvist et al. (59) reported reductions in
high energy metabolic substrates (adenosine triphosphate 
[ATP], PCr and glycogen), in contrast to Sullivan's report (57) 
that ATP and PCr were unchanged. Other investigators have 
found a reduction in phosphofructokinase ctivity in patients 
with CHF (60). 
Taken together, the histologic and biochemical changes 
suggest a switch, from aerobic to anaerobic metabolism in the 
skeletal muscle of patients with chronic heart failure, and a 
reduction in the activity of oxidative enzymes. Some of the 
reduction of enzyme activity might be explained by changes in 
the fiber type and structural changes. Other potential impor- 
tant biochemical changes as determinants of exercise tolerance 
have not been examined in detail, however. For example, 
muscle sodium-potassium ATPase appears to be reduced (61). 
Some other abnormality of membrane channel or receptor 
(62) or of the contractile apparatus could prove more impor- 
tant. 
Function. Skeletal muscle is functionally abnormal in 
CHF. We have found a reduction in quadriceps muscle 
strength (53) and an association between quadriceps trength 
and exercise performance (63). Other workers have not found 
a reduction in skeletal muscle strength (64,65), possibly be- 
cause loss of skeletal muscle bulk may be an important 
determinant of strength (52)--mean force per unit area was 
within the normal range, implying that myofibril force produc- 
tion was normal. From the patient's point of view, the ability to 
perform repeated submaximal exercise is more important than 
peak force generation, and early quadriceps fatiguability has 
been reported (52,65). This reduction in endurance correlates 
with exercise performance, ashas been found by other inves- 
tigators (66). 
Fatigue appears to be independent of acute changes in 
blood flow (64,65) and of central factors (66). Fatiguability has 
been shown in a very small muscle group in which blood flow 
is unlikely to be limited by cardiac reserve (63), suggesting that 
intrinsic muscle factors mediate fatiguability of muscle. 
Muscle bulk. Muscle wasting in CHF has been recognized 
since ancient imes (67). Decreased muscle bulk could poten- 
tially explain many of the observed lower limb abnormalities 
seen in CHF, such as an increase in fatigue and a decrease in
exercise tolerance as a result of increased load per unit 
myofibril and a proportionate r duction in leg blood flow. The 
increased vascular resistance might result partly from the 
decreased vascular conductance purely on anatomic grounds. 
Mancini et al. (68) showed that muscle wasting occurred even 
in mild heart failure. Further, they showed that peak exercise 
capacity correlated with calf muscle volume. We found that 
exercise capacity correlated with both strength and muscle 
mass, and that reduced leg blood flow may be a consequence of 
muscle wasting (69). 
Minotti et al. (70) found a reduction in muscle size and 
endurance. Maximal force per unit of muscle remained un- 
changed. These observations lend further support o the idea 
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that muscle wasting may be the key event, so that strength may 
be reduced while maximal force per unit muscle is not im- 
paired, at least in mild to moderate heart failure. Nevertheless, 
there also appears to be a qualitative difference between 
normal and heart failure muscle, as fatigue was not fully 
explained by the reduction in muscle size. This may be related 
to muscle quality or to alterations in gross structure, such as 
intramuscular fat content. 
Muscle metabolism. In CHF, there is early onset of intra- 
muscular acidosis and excessive lactate production, often mea- 
sured as an increase in arterial and venous lactates at a given 
work load (71,72), and a lower ventilatory anaerobic threshold 
(46,73). Katz et al. (74) found that during 30 min of submaxi- 
mal exercise (at two thirds of the previously determined peak 
"+'o2), femoral venous and arterial lactate levels were un- 
changed, although lactate turnover was twice that at rest. 
Simple measures of arterial or venous lactate are only poorly 
related to the metabolic state of the exercising muscle. 
The metabolic onsequences of exercise can be explored 
using phosphorus-31 (31p) nuclear magnetic resonance spec- 
troscopy. The relative concentrations of inorganic phosphate 
(Pi),  PCr and ATP can be determined from analysis of 
phosphorus spectra. Arm muscle demonstrates more rapid 
depletion of PCr in patients with CHF than in control subjects 
(75-77), and these findings have been extended to the lower 
limb. Mancini et al. (78) used circulatory occlusion to "freeze" 
the metabolic state of the muscle at peak exercise (79). 
Mancini et al. showed that the slope of the increase in Pi/PCr 
relative to "~o 2 was increased in the calf muscle in patients 
with CHF; that is, at any given work load there was greater 
depletion of PCr. The rate at which PCr was resynthesized 
was slower in the patients. 
Using a larger coil to allow leg exercise inside the magnet, 
Arnolda et al. (80) showed a seven times greater fall in the 
PCr/(PCr + Pi) ratio in patients with heart failure during the 
early stages of plantar flexion exercise. At peak exercise, the 
PCr/(PCr + Pi) ratio and pH were lower than in control 
subjects. In this small study of seven patients, recovery of PCr 
after exercise was not significantly slower in patients with CHF. 
Simultaneous leg blood flow measurements showed that blood 
flows at a given level of exercise were the same in both patients 
and control subjects, afurther indication that blood flow itself 
is not a determinant of muscle metabolism, at least acutely. 
Mancini et al. (54) also showed no relation between histo- 
logic and biochemical abnormalities and magnetic resonance 
spectroscopic variables. This later finding suggests that the 
observed histologic and biochemical changes do not closely 
predict the abnormal metabolic response. Marie et al. (81) 
found that the load taken to achieve a given level of PCr 
depletion during calf exercise was about one third of that in 
normal subjects. Mancini et al. (68) also analyzed the time 
constant of recovery for PCr. This variable is said to be 
independent of work load and muscle mass used. The constant 
correlated better with work slope than did measures of muscle 
mass, which has been interpreted as suggesting that intrinsic 
alterations ofmuscle fibers rather than atrophy (at least as far 
as external muscle size is concerned) are the dominant mech- 
anisms for reduced exercise tolerance (82). 
Some of these findings apparently contradict the findings of 
Sullivan et al. (57) of less lactate generation and less PCr 
decline at peak exercise on muscle biopsy studies. This may be 
because in their study maximal exercise was used, whereas in 
the magnetic resonance spectroscopy studies, smaller muscle 
groups were used. With a small muscle group, exercise capacity 
may be determined by the metabolic apacity of the muscle 
alone, whereas with cycle exercise to exhaustion, other limiting 
factors, such as cardiac output, muscle blood flow and venti- 
latory response, may become more important determinants of 
exercise capacity. 
Origins of Muscle Changes 
Peripheral hemodynamie variables. The origin of the his- 
tologic and biochemical bnormalities must ultimately be due 
to heart failure, although there is no consensus on how this 
comes about. A reduction in blood flow to the exercising 
muscle seems a likely possibility. Wilson et al. (83) found a 
reduction in blood flow to exercising leg muscle in patients 
with CHF compared with control subjects. The delayed im- 
provement in exercise capacity seen after treatment with 
angiotensin-converting e zyme inhibitors is correlated closely 
with the increase in leg blood flow (20). There is near maximal 
oxygen extraction by exercising muscle, and the widened 
arteriovenous oxygen difference (20,84) suggests that the ex- 
ercising muscles' activity is being limited by the capacity of the 
circulation to deliver oxygen. 
A decrease in blood flow to the periphery might be ex- 
plained by abnormalities of vasomotor tone (85). There is a 
reduced response to endogenous vasodilatory stimuli (86,87), 
to infused hyperosmolar solutions (88) and to pharmacologic 
agents (89). Alternatively, an increase in levels of endothelin or 
a reduction in response to endothelial vasodilatory capacity 
may contribute (90). LeJemtel et al. (91) showed that the 
peripheral resistance isgreatly elevated inCHF. The site of the 
increased peripheral resistance is not yet understood. An 
increase in the arterial wall sodium has been reported in an 
experimental model (92); this could result in smooth muscle 
contraction within the arterial walls. The muscle capillary 
structure appears normal, and although the capillary basement 
membrane appears thickened in CHF, the difference between 
patients and control subjects is small (93). Arterioles are more 
difficult to examine, but recent studies have suggested that 
hyalinosis within terminal arterioles correlated with an in- 
creased minimal vascular esistance in patients with dilated 
cardiomyopathy (94). Large artery abnormalities have also 
been observed (95). 
The relation between leg blood flow and exercise capacity is 
more complex than these findings suggest. Wilson et al. (96) 
used dobutamine to cause an immediate improvement in leg 
blood flow. At any given work load, the lactate response to 
exercise was unchanged, rawing attention to the possible 
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distinction between blood flow and "nutritive flow." Further, 
Wilson et al. (97) reported a subset of patients with normal 
femoral blood flow on exercise, who had abnormal leg muscle 
as lactate production was increased, compared with normal 
subjects. There appear to be abnormalities of leg muscle that 
are independent of changes in blood flow. There seems to be 
no relation between leg blood flow and exercise capacity (69). 
Alterations in muscle biochemistry thus appear to be intrinsic, 
and do not depend, at least acutely, on alterations in blood 
f low. 
The changes een in patients with CHF are similar to those 
seen in normal subjects undergoing "detraining," with skeletal 
muscle wasting and depletion of oxidative nzymes (98,99) and 
activation of the sympathetic (100) and renin-angiotensin (101 )
systems. Possible mechanisms for muscle wasting include mal- 
nutrition and malabsorbtion (102,103) and an increase in 
myofibrillar breakdown (104). In patients with ischemic heart 
disease, skeletal muscle ischemia may be another factor (105). 
Chronic hypoxia in normal subjects causes a reduction in fiber 
size and a decrease in aerobic enzymes (106). However, studies 
of detraining have shown generalized fiber wasting and no 
change in the distribution of muscle fiber types (107,108), 
although training can result in a shift toward type I and IIa 
fibers (109). The fact that changes are seen in small arm 
muscles uggests that simple disuse is unlikely to be the only 
contributor to the muscle changes. 
The generalized activation of the sympathetic system seen 
in CHF could act as a further mediator of skeletal muscle 
change, together with a possible contribution from catabolic 
factors and loss of anabolic function. Increased sympathetic 
efferent activity is seen early in the clinical course of the 
disease (110). Tumor necrosis factor has been found to be 
elevated (111,112). Insulin resistance isalso present in patients 
with CHF (113), and the insulin resistance found may contrib- 
ute to muscle catabolism. The persistent sympathetic activa- 
tion seen in CHF is not well explained. It is often thought o be 
due to chronic withdrawal of baroreflex inhibition by reduced 
perfusion pressure. However, the baroreflex gain is greatly 
reduced in CHF (114-116), and ultrafiltration to remove over 
31 body fluids, while resulting in a fall in blood pressure, results 
in suppression of the neurohormonal xis (117). 
The existence of ergoreceptors (118) or metaboloreceptors 
(119) sensitive to muscle work and transmitting to the central 
nervous ystem through small unmyelinated nerve fibers (120) 
and enhanced by accumulation of metabolites (121,122) sug- 
gests a different "vicious cycle." These chemically sensitive 
afferent fibers from muscle drive blood pressure responses and 
increase sympathetic a tivity in normal subjects (123-125), and 
the presence of increased ergoreceptor activity in CHF (126) 
might maintain the increased sympathetic outflow, increasing 
peripheral resistance and decreasing skeletal muscle perfusion 
(85-92). In turn, the skeletal muscle may deteriorate further. 
These receptors and their afferent fibers may mediate the 
sensation of fatigue and possibly breathlessness. 
Evidence From Exercise Training 
Early corrective changes in hemodynamic variables in CHF 
are not accompanied by early increases in exercise capacity 
(19-23). Exercise training regimens have been shown to have 
beneficial effects on exercise capacity (12%130). There may be 
an improvement in cardiac performance with training (131), 
but the majority of the training effect is seen in the periphery. 
There are improvements in forearm metabolic apacity with 
training (132) and increased leg blood flow secondary to a 
reduction in leg vascular esistance (127). There is a decrease 
in the lactate rise during exercise, associated with an increase 
in the ventilatory anaerobic threshold (133). Adamopoulos et 
al. (134) have shown improvements in the leg metabolic 
abnormalities measured by 31p magnetic resonance spectros- 
copy with training, and the arm abnormalities are at least 
partially reversed (135). The improvements in exercise capacity 
appear to occur largely in the absence of improvements in
central hemodynamic function (136,137). Training also causes 
a decrease in the ventilatory response to exercise (138). 
Skeletal Muscle and Ventilation in CHF 
What is the relation between exercise limitation, increased 
ventilation, skeletal muscle changes and symptoms of chronic 
heart failure? Kraemer et al. (139) found a relation between 
spirometric variables and peak "v'o2, but this could simply 
reflect a general relation between muscle strength and exercise 
capacity. Dyspnea could result from respiratory muscle 
changes, such as increased iaphragmatic work and accessory 
muscle deoxygenation (140,141), and reduced respiratory mus- 
cle strength (142,143). This hypothesis does not explain the 
increase in VENCO2 slope. It may be that there is a specific 
ventilatory signal arising from exercising muscle (possibly 
including respiratory muscle), which is abnormally enhanced in 
CHF. 
Circulating metabolites have been proposed as ventilatory 
stimuli. Lactic acid production has been considered, but the 
time course of the rise in lactate does not closely follow that of 
the rise in ventilation (144,145). Patients with McArdle's 
syndrome are unable to generate lactate and yet still show an 
increase in ventilation with exercise (146). Further, dichloro- 
acetate administration in patients with CHF prevents the 
exercise-induced rise in lactate but does not alter peak exercise 
capacity or ventilation (147). 
Arterial potassium rises during exercise and closely follows 
the time course of the ventilatory response (145,148). The rise 
in potassium ay be greater at matched work loads in patients 
with CHF (149). Intracellular calcium rises during exercise, 
causing an increase in potassium conductance, leading in turn 
to an inactivated membrane. This potential protective mecha- 
nism, preventing an excessive rise in intracellular calcium 
during excessive work, may equate with fatigue (150). We 
found no relation between the rise in arterial and venous 
potassium and the rise in ventilation in patients with CHF. The 
potassium rise parallelled the rise in 'v'o2 rather than that in 
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VE. The implication of this experiment is that both potassium 
and carbon dioxide are independent of the cause of the 
increase in ventilation (151), both reflecting the amount of 
exercise performed. Moreover, in patients undergoing treat- 
ment with erythropoietin for the anemia of chronic renal 
failure, the ventilatory response to exercise fell, while there was 
an increase in circulating potassium concentrations (152). 
Nevertheless, as a local intramuscular mediator, potassium 
may be important--perhaps being a natural stimulant of the 
muscle ergoreceptor. 
There may be alternative humoral ventilatory stimuli. Tibes 
et al. (144) found no evidence for a range of possible metab- 
olites in normal subjects. There could be an alteration in 
chemoreceptor responsiveness at the onset of exercise so that 
those with a greater ventilatory response develop an increase 
in chemoreceptor sensitivity. In preliminary studies of normal 
subjects, we found no evidence for this possible effect-- 
exercising with cuffs inflated around the thighs to suprasystolic 
pressure results in an increase in VENCO2 slope, which could 
not be of humoral origin (153), although a neural link to 
increased chemoreceptor sensitivity is possible. 
The ergoreceptors postulated earlier to have a role in the 
vicious cycle of sympathetic a tivation and muscle wasting may 
also be related to the ventilatory response to exercise; during 
exercise in normal subjects, there is a signal arising from 
exercising muscle that stimulates ventilation, and is enhanced 
by circulatory occlusion (154). Data from our laboratory 
suggest that the ventilatory stimulus in normal subjects is 
related to the muscle bulk being used rather than the external 
work load being performed, and that the response isenhanced 
by circulatory occlusion to the exercising muscles (153) and is 
more marked if a smaller muscle group performs the same 
work load during exercise. 
Fatigue and Termination of Exercise 
Ultimately, incremental exercise stops with a voluntary 
decision made by the exerciser in response to unwelcome 
symptoms, usually fatigue or breathlessness. Most studies of 
exercise capacity have used cycle exercise, particularly in the 
United States, and cycle exercise is usually terminated by 
fatigue (5). Treadmill exercise, more common in the United 
Kingdom, is more frequently terminated by shortness of breath 
(12). The same patient may complain of different symptoms 
depending on the type of exercise undertaken (8). There is no 
difference in cardiac function and ventilatory responses be- 
tween those patients stopping owing to breathlessness and 
those stopping owing to fatigue (12). It is not clear that fatigue 
and this form of dyspnea re discrete phenomena. 
It might be thought hat fatigue should be related to the 
metabolic state of the muscles, particularly to lactate accumu- 
lation. In normal subjects, reducing the blood flow to the 
exercising leg results in early anaerobic metabolism but a lower 
than usual lactate at peak exercise (155). In CHF, lactate 
reduction causes no change in leg blood flow or exercise 
capacity (147), again suggesting that lactate is not an important 
mediator of fatigue. The sensation appears not to be related to 
PCr usage--chronic hypoxia leads to less PCr reduction at the 
same level of fatigue (156). Other possible sites for the 
generation of fatigue have been identified, including intramus- 
cular potassium (150). The possibility that the sensation of 
fatigue is generated as a central mechanism to protect against 
hypoxic damage to essential organs (157,158) is attractive. 
Nevertheless, muscie factors appear to be important as 
determinants of exercise. In contrast o hemodynamic vari- 
ables, muscle bulk is a good predictor of peak "~o 2 (68-70). 
This again raises the possibility that the ergoreceptors may be 
important; the same receptors may be responsible for mediat- 
ing both dyspnea nd the sensation of fatigue. 
Implications. The therapeutic response in CHF to inotrop- 
ic agents has been disappointing, with an increase in mortality 
after therapy with, for example, milrinone (159), flosequinan 
(160) and xamoterol (161); although some of these agents have 
proved to have symptomatic benefit (162). Vasodilators appear 
to result in a decrease in mortality in heart failure (163-165), 
but the effect does not depend only on vasodilation; angiotensin- 
converting enzyme inhibitors are more effective at reducing 
mortality than other vasodilators, despite similar degrees of 
vasodilation (166,167). Indeed, the evidence that vasodilators 
other than angiotensin-converting enzyme inhibitors benefit 
mortality is doubtful (168,169). Improvements in mortality may 
depend on effects on the neurohormonal bnormalities of 
heart failure (170). 
The muscle hypothesis (171) (Fig. 1) suggests new strategies 
for intervention. The major determinant of symptoms in 
chronic heart failure may be the abnormalities of skeletal 
muscle, resulting in early fatigue and an increase in the 
ventilatory stimulus and thus an increased ventilatory response 
to exercise. The key abnormalities are bulk, blood flow and 
function. The abnormal muscle results in persistent activation 
of the sympathetic nervous system, with increased afterload 
and reduced peripheral blood flow. In turn, cardiac function 
deteriorates with further patient inactivity, causing further 
deterioration i skeletal muscle. In addition, a catabolic state 
exists, further causing muscle wasting, perhaps related to 
cytokine activation and insulin resistance. Rather than treating 
the consequences of this proposed cycle of deterioration, ACE 
inhibitors and exercise training interrupt it, at least partially. 
Conclusions 
The evidence presented in this report suggests that new 
forms of treatment focused on skeletal muscle may improve 
the patient's quality of life. If exercise training can prevent a 
deleterious cycle, it may even slow or arrest progression of the 
disorder. Exercise training has been shown to modify some of 
the predictors of mortality in chronic heart failure (128). It may 
prove possible in the future to improve skeletal muscle func- 
tion pharmaceutically, perhaps with anabolic steroids or beta 2
adrenoceptor agonists (172), or even with pharmacologic 
"training" (173). 
The evidence presented here does not prove that central 
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Figure 1. Muscle hypothesis in CHF. Skeletal muscle is 
abnormal in CHF. During exercise, muscle has a limited 
capacity for aerobic metabolism, resulting in fatigue and 
ergoreflex activation, which causes an increase in the venti- 
latory response to exercise and the sensation of dyspnea. 
Ergoreflex activation also causes sympathetic nervous sys- 
tem activation, with a consequent increase in afterload and 
a decrease in blood flow to the periphery, further exacer- 
bating skeletal muscle abnormalities. 
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hemodynamic variables are unimportant. In the genesis of the 
heart failure syndrome, an initial cardiac abnormality is essen- 
tial. Similarly, abnormalities of pulmonary function have been 
found by many investigators and may contribute to breathless- 
ness and exercise limitation. The syndrome of chronic heart 
failure causes changes in many body systems and may repre- 
sent a heterogeneous condition with some patients limited by 
pulmonary abnormalities, some by blood flow and some by 
skeletal muscle changes. Treatment aimed at the heart alone 
may not be the most successful approach. The potential 
importance of skeletal muscle abnormalities offers new possi- 
bilities for treatment of a common and debilitating condition. 
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